Mid Face Lift — Cost, Top Hospitals & Success Rates | MyMedicPlus

The mid face lift — also called a cheeklift or malar lift — is a surgical procedure that repositions the soft-tissue compartments of the central facial third: from the lower eyelid margin superiorly down to the nasolabial fold inferiorly. Unlike a traditional SMAS facelift, which primarily addresses the lower face and jowls, the mid face lift targets structures that descend with age in the cheek zone.

Facial ageing in the midface is driven by volume redistribution and soft-tissue descent rather than skin laxity alone. The malar fat pad — a discrete subcutaneous fat compartment — migrates inferomedially with age, deepening the nasolabial fold and creating a concavity beneath the lower eyelid known as the tear trough or nasojugal groove. Concurrently, descent of the orbicularis oculi muscle and orbital fat pseudoherniation produce lower lid laxity and festoons (malar mounds).

Anatomically, the midface contains multiple discrete fat compartments: the superficial medial cheek fat, the middle cheek fat, the deep medial cheek fat (adjacent to the levator labii), the suborbicularis oculi fat (SOOF), and the buccal fat pad deeper still. Understanding these compartments is critical to choosing between volumetric (filler/fat) and structural (surgical lift) approaches.

Midface lifting techniques vary in the anatomical plane they address — subcutaneous only, SMAS-based (composite), or sub-periosteal (deep plane/endoscopic) — with longevity and invasiveness increasing along that spectrum.

The mid face lift is indicated for the following age-related changes in the central facial third:

• Malar fat pad descent: Inferior and medial migration of the cheek fat causing loss of the youthful triangular facial highlight over the zygoma.
• Deepened nasolabial folds: Accumulation of ptotic tissue in the nasolabial crease — a direct consequence of malar fat descent rather than skin excess alone.
• Tear trough and nasojugal groove: Depression along the medial lower lid-cheek junction where the orbicularis retaining ligament tethers skin while surrounding tissue descends.
• Lower eyelid laxity and festoons: Edematous swelling or loose skin of the lower lid, sometimes accompanied by malar mounds caused by chronic lymphatic congestion and orbicularis descent.
• Flattened malar eminence: Loss of cheek prominence and the characteristic high-cheekbone contour of youth.
• Midface volume deficit: Skeletal remodelling and fat atrophy causing a skeletonised appearance even without significant ptosis.

Importantly, the mid face lift corrects ptosis and descent — it is not a volume procedure in itself, though it is frequently combined with fat grafting or fillers to address concurrent volume loss.

Appropriate patient selection is the single most important determinant of outcome. The ideal candidate has:

• Age range typically 40–60 years with early-to-moderate midface descent
• Primarily ptotic midface changes (tissue that has fallen but is not significantly atrophic)
• Good residual skin elasticity — minimal skin excess in the mid-cheek zone
• BMI in a stable, healthy range (significant obesity impairs healing and distorts contour)
• Non-smoker, or willingness to cease smoking ≥6 weeks before and after surgery
• Realistic expectations regarding improvement (not elimination) of nasolabial folds

Relative contraindications include:

• Significant skin excess of the lower face requiring a traditional facelift — a mid face lift alone will not correct jowls or neck laxity
• Prior extensive facial surgery or radiation that has disrupted tissue planes
• Coagulopathy or anticoagulant therapy that cannot be safely paused
• Active facial skin infection or dermatitis
• Unrealistic expectations or body dysmorphic disorder (formal psychological assessment recommended)

Patients with combined lower-face and midface ageing are better served by a composite or deep plane facelift that addresses both zones simultaneously rather than two separate operations.

Multiple operative techniques exist, each addressing different anatomical planes with distinct risk-benefit profiles:

1. Subcutaneous (Skin-Only) Lift

The most superficial approach involves undermining the skin and advancing it supero-laterally. It provides modest improvement and the shortest longevity (2–3 years), as it does not address the deeper ptotic structures. No longer favoured as a standalone technique.

2. SMAS-Based Composite Facelift

The superficial musculoaponeurotic system (SMAS) is the fibromuscular layer deep to the subcutaneous fat. SMAS manipulation is the modern standard. Techniques include lateral SMAS plication, SMASectomy, and the composite flap (SMAS elevated in continuity with overlying skin and orbicularis). The composite flap directly lifts the malar fat pad because it is included in the elevated tissue. Results last 5–8 years.

3. Deep Plane Facelift

Popularised by Sam Hamra, the deep plane release allows the entire cheek-SMAS unit to be mobilised as a single composite flap by releasing the zygomatic and masseteric-cutaneous retaining ligaments. This achieves the most powerful midface repositioning with a single vector and provides the longest-lasting correction (8–12 years). The sub-SMAS plane is safer than superficial planes regarding facial nerve injury, as the nerve branches are deep to the SMAS anteriorly.

4. Endoscopic Midface Lift (Temporal Approach)

Performed through small temporal and intraoral incisions using an endoscope, this technique elevates the midface in the sub-periosteal plane and suspends it to the deep temporal fascia with sutures or fixation devices. Benefits include no visible scars on the cheek; limitations include limited correction of skin excess and a steeper learning curve.

5. Thread Lift (Non-Surgical Adjunct)

Absorbable barbed sutures (PDO or PLLA) placed percutaneously can provide temporary midface elevation (12–18 months). Not equivalent to surgical lifting but useful as a temporising measure or in patients unwilling to undergo surgery.

6. Combined with Lower Blepharoplasty

Midface lifting is synergistic with lower lid surgery: lifting the cheek reduces tension on the lower lid, decreasing the risk of scleral show and ectropion. The orbicularis muscle, elevated with the cheek, also rejuvenates the lower lid junction. Most surgeons performing lower blepharoplasty in patients with midface descent will recommend addressing both zones simultaneously.

7. Volume Restoration (Adjunct Procedures)

Surgical lifting alone does not restore lost volume. Options combined with mid face lift include:

• Structural fat grafting (Coleman technique): Harvested autologous fat micro-injected into the malar eminence, tear trough, and nasolabial fold. Approximately 50–70% of transferred fat survives long-term. Results are permanent once fat cells establish a blood supply.
• Cheek implants: Solid silicone malar or submalar implants placed sub-periosteally to augment bony projection. Appropriate when the underlying skeleton is deficient rather than when soft tissue ptosis is the primary issue.
• Hyaluronic acid fillers: Non-surgical option for volume; typically lasting 12–24 months depending on product. Not a lift but restores the appearance of volume in the depleted cheek.

When performed on an appropriately selected patient by an experienced surgeon, a mid face lift delivers the following outcomes:

• Restoration of the ogee curve: The S-shaped contour of a youthful cheek — convex superiorly at the zygomatic mound, concave at the submalar hollow — is re-established.
• Improvement in nasolabial folds: Repositioning the malar fat pad directly reduces the fold by removing the tissue burden that creates it. This is more effective than filler, which fills rather than corrects the anatomical cause.
• Lower eyelid rejuvenation: The ascending cheek fills the tear trough zone and supports the lower lid, reducing the skeletonised appearance.
• Longevity: Subcutaneous lifts last 2–3 years; SMAS-based techniques 5–8 years; deep plane approaches 8–12+ years — all superior to injectable treatments (typically 12–24 months).
• Natural appearance: Deep plane techniques avoid the pulled, windswept appearance associated with skin-only lifting because they reposition tissue along natural anatomical vectors.
• Synergy with adjacent procedures: The mid face lift complements lower blepharoplasty, rhinoplasty, and neck lift, allowing comprehensive facial rejuvenation in one operative session.

Mid face lift surgery carries risks common to all facial procedures as well as technique-specific concerns:

Common Risks

• Haematoma: Occurs in 1–3% of cases; higher in hypertensive patients. Requires prompt drainage to prevent skin compromise.
• Prolonged swelling and bruising: Sub-periosteal and deep plane approaches produce more oedema than superficial techniques; cheek swelling can persist 6–12 weeks.
• Temporary sensory changes: Numbness or tingling in the cheek, particularly over the zygoma, due to retraction of the zygomaticotemporal nerve. Typically resolves within 3–6 months.
• Infection: Rare (<1%); risk increased with intraoral incision access.
• Scarring: Temporal and preauricular scars generally heal well; poor healing is more common in smokers.

Technique-Specific Risks

• Facial nerve injury: The temporal branch (forehead/brow movement) and the zygomatic branch (lower eyelid closure) are at greatest risk. Permanent injury is rare (<0.5%) in experienced hands; transient paresis is more common with aggressive SMAS dissection.
• Lower eyelid malposition (ectropion or scleral show): More common when midface surgery is combined with lower blepharoplasty without careful vector planning.
• Fat graft resorption: Unpredictable; over-correction at time of surgery is therefore standard practice.
• Under-correction or recurrence: Patients with very lax skin or high body weight may experience early relapse of midface descent.

Limitations

A mid face lift does not address: lower facial jowls, platysmal banding in the neck, eyelid skin excess (blepharochalasis), or lip lines. Patients with pan-facial ageing require a more comprehensive operative plan.

Recovery from a mid face lift follows a predictable timeline, though the pace depends on the technique used and the extent of combined procedures:

• Days 1–3: Head elevation maintained at 30–45 degrees at all times to reduce oedema. Bruising and swelling peak. Ice packs applied intermittently.
• Days 4–10: External sutures removed (temporal, preauricular). Significant ecchymosis begins to fade. Most patients feel comfortable at home.
• Weeks 2–3: Patients are typically comfortable returning to social settings with make-up to cover residual bruising. Sub-periosteal approaches may have more persistent cheek firmness.
• Weeks 4–6: Light exercise resumed. Facial massage (per surgeon guidance) may begin to soften scar tissue.
• Months 3–6: Final results emerge as residual oedema completely resolves and soft tissues settle into their new position. Numbness and tightness continue to improve.

Key post-operative instructions:

• Avoid vigorous exercise, bending, and straining for 4 weeks
• Sleep on back with head elevated for 2–4 weeks
• Sun protection (SPF 50+) on scars for 12 months
• Avoid NSAIDs and blood-thinning supplements (fish oil, vitamin E) for 2 weeks post-operatively unless clinically required
• Cease smoking completely — nicotine-induced vasoconstriction dramatically increases risk of skin flap ischaemia

Mid face lift surgery costs vary widely based on technique complexity, geographic location, and whether it is performed as a standalone or combined procedure:

• United States: USD 8,000–20,000 for an isolated mid face lift; USD 20,000–45,000 when combined with full facelift and blepharoplasty
• United Kingdom: GBP 7,000–18,000
• India (Mumbai, Delhi, Bangalore): USD 3,000–7,000 — board-certified plastic surgeons trained at Western institutions, NABH-accredited facilities
• Thailand (Bangkok): USD 4,000–9,000 — JCI-accredited hospitals; established medical tourism infrastructure
• Turkey (Istanbul): USD 3,500–8,000 — high surgeon volume, competitive pricing

Key cost components include:

• Surgeon fee (largest component; reflects experience and technique)
• Anaesthesia fee (general anaesthesia vs. deep sedation)
• Operating theatre and facility fee
• Pre-operative assessment (blood tests, anaesthesia review)
• Post-operative garments, medications, and follow-up visits
• Adjunct procedures (fat grafting, blepharoplasty) billed separately

Mid face lift is an elective cosmetic procedure and is not covered by health insurance in most countries. Patients travelling internationally for surgery should budget for at least one week of local recovery time and should verify surgeon credentials (board certification in plastic surgery equivalent), hospital accreditation, and have a plan for local follow-up care on return.

For patients who are not surgical candidates, prefer non-invasive options, or wish to delay surgery, effective alternatives exist on a spectrum of invasiveness and longevity:

Injectable Treatments

• Hyaluronic acid fillers (malar augmentation): Products such as Juvederm Voluma, Sculptra Aesthetic (poly-L-lactic acid), or Radiesse can restore malar volume and reduce tear trough deformity non-surgically. Effect lasts 12–24 months. Does not reposition ptotic tissue but compensates for volume loss.
• Anti-wrinkle injections (botulinum toxin): Limited role in the midface but can relax the depressor anguli oris and nasal dilator alar muscles to create modest lifting of the nasolabial corner.

Energy-Based Devices

• Ultherapy (Microfocused Ultrasound): Delivers focused ultrasound energy to the SMAS layer, stimulating collagen remodelling. Provides modest lifting (1–2 mm) in the brow and midface over 3–6 months. Suitable for mild ptosis.
• Thermage (Radiofrequency): Skin tightening through collagen contraction; modest results in early skin laxity.
• Fractionated CO2 laser resurfacing: Addresses surface texture, fine lines, and mild skin laxity but does not reposition deep tissues.

Structural Fat Grafting (Standalone)

When midface hollowing rather than tissue ptosis is the dominant concern, autologous fat transfer alone (without a lift) can restore youthful volume. This is a surgical procedure performed under sedation with minimal downtime compared to a facelift.

Cheek Implants

Solid silicone malar implants placed sub-periosteally provide permanent structural augmentation. Appropriate for patients with true skeletal deficiency (hypoplastic malar bone) rather than soft-tissue descent. Not a substitute for lifting in patients with significant ptosis.